Magazine Article | December 7, 2017

Are You Ready For The Future Of Biopharma Manufacturing?

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

In last’s year’s manufacturing outlook we delved into biopharma’s manufacturing capacity crunch. While lack of manufacturing capacity remains a challenge for the industry, the future of biopharma manufacturing has never looked so bright, and there is a variety of reasons why. For starters, when it comes to innovation in manufacturing, biopharma companies continue to push the envelope. Want proof? Take a quick review of the ISPE Facility of the Year Awards (FOYA), an annual program recognizing state-of-the-art projects by biopharma manufacturers. There you’ll see some old standbys (e.g., Abbott, Bristol-Myers Squibb, and Lilly) being recognized for operational excellence (OPEX), facility integration, and process innovation, but you’ll also encounter some lesser-known names. For example, Kalbio Global Medika’s young team (average age of 24) received an honorable mention for its 40,000-square-foot biotechnology manufacturing build in Jakarta, Indonesia. Nephron Pharmaceuticals Corp., another honorable mention, is a woman-owned business that also happens to be the world’s largest blow-fill-seal manufacturer.

THIS CONTENT IS EXCLUSIVELY FOR LIFE SCIENCE LEADER PAID SUBSCRIBERS.
To continue reading this story and receive uninterrupted access to LSL Online and its monthly magazine subscribe to Life Science Leader today!
Already a subscriber? Log in now.